Research ArticleOriginal Article

Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library

Yuanzhong Wu, Liwen Zhou, Zifeng Wang, Xin Wang, Ruhua Zhang, Lisi Zheng and Tiebang Kang
Cancer Biology & Medicine August 2020, 17 (3) 782-794; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0162

References

  1. 1.↵
    2. Gianferante DM,
    3. Mirabello L,
    4. Savage SA.
    Germline and somatic genetics of osteosarcoma – connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017; 13: 480–91.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Zambo I,
    3. Vesely K.
    [WHO classification of tumours of soft tissue and bone 2013: the main changes compared to the 3rd edition]. Cesk Patol. 2014; 50: 64–70.
    OpenUrlPubMed
  3. 3.↵
    2. Ottaviani G,
    3. Jaffe N.
    The epidemiology of osteosarcoma. Cancer Treat Res. 2009; 152: 3–13.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Link MP,
    3. Goorin AM,
    4. Miser AW,
    5. Green AA,
    6. Pratt CB,
    7. Belasco JB, et al.
    The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314: 1600–6.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    2. Meyers PA,
    3. Healey JH,
    4. Chou AJ,
    5. Wexler LH,
    6. Merola PR,
    7. Morris CD, et al.
    Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer. 2011; 117: 1736–44.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Bishop MW,
    3. Janeway KA,
    4. Gorlick R.
    Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2016; 28: 26–33.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Yu XW,
    3. Wu TY,
    4. Yi X,
    5. Ren WP,
    6. Zhou ZB,
    7. Sun YQ, et al.
    Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol. 2014; 35: 155–60.
    OpenUrlCrossRefPubMed
  8. 8.
    2. Grignani G,
    3. Palmerini E,
    4. Dileo P,
    5. Asaftei SD,
    6. D’Ambrosio L,
    7. Pignochino Y, et al.
    A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012; 23: 508–16.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. Sulzbacher I,
    3. Birner P,
    4. Trieb K,
    5. Traxler M,
    6. Lang S,
    7. Chott A.
    Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol. 2003; 16: 66–71.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    2. Kantoff PW,
    3. Higano CS,
    4. Shore ND,
    5. Berger ER,
    6. Small EJ,
    7. Penson DF, et al.
    Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411–22.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.
    2. Brahmer JR,
    3. Tykodi SS,
    4. Chow LQ,
    5. Hwu WJ,
    6. Topalian SL,
    7. Hwu P, et al.
    Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455–65.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    2. Kansara M,
    3. Teng MW,
    4. Smyth MJ,
    5. Thomas DM.
    Translational biology of osteosarcoma. Nat Rev Cancer. 2014; 14: 722–35.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Tavanti E,
    3. Sero V,
    4. Vella S,
    5. Fanelli M,
    6. Michelacci F,
    7. Landuzzi L, et al.
    Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer. 2013; 109: 2607–18.
    OpenUrl
  14. 14.↵
    2. Robert F,
    3. Huang S,
    4. Pelletier J.
    CRISPR/Cas9 editing to facilitate and expand drug discovery. Curr Gene Ther. 2017; 17: 275–85.
    OpenUrl
  15. 15.↵
    2. Cong L,
    3. Ran FA,
    4. Cox D,
    5. Lin S,
    6. Barretto R,
    7. Habib N, et al.
    Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339: 819–23.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Mali P,
    3. Yang L,
    4. Esvelt KM,
    5. Aach J,
    6. Guell M,
    7. DiCarlo JE, et al.
    RNA-guided human genome engineering via Cas9. Science. 2013; 339: 823–6.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Shalem O,
    3. Sanjana NE,
    4. Hartenian E,
    5. Shi X,
    6. Scott DA,
    7. Mikkelsen TS, et al.
    Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014; 343: 84–7.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Wang T,
    3. Wei JJ,
    4. Sabatini DM,
    5. Lander ES.
    Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014; 343: 80–4.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    2. Koike-Yusa H,
    3. Li Y,
    4. Tan EP,
    5. Velasco-Herrera Mdel C,
    6. Yusa K.
    Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol. 2014; 32: 267–73.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Steinhart Z,
    3. Pavlovic Z,
    4. Chandrashekhar M,
    5. Hart T,
    6. Wang X,
    7. Zhang X, et al.
    Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat Med. 2017; 23: 60–8.
    OpenUrlCrossRefPubMed
  21. 21.↵
    2. Yamauchi T,
    3. Masuda T,
    4. Canver MC,
    5. Seiler M,
    6. Semba Y,
    7. Shboul M, et al.
    Genome-wide CRISPR-Cas9 screen identifies leukemia-specific dependence on a pre-mRNA metabolic pathway regulated by DCPS. Cancer Cell. 2018; 33: 386–400.e5.
    OpenUrl
  22. 22.↵
    2. Knott GJ,
    3. Doudna JA.
    CRISPR-Cas guides the future of genetic engineering. Science. 2018; 361: 866–9.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Chan EM,
    3. Shibue T,
    4. McFarland JM,
    5. Gaeta B,
    6. Ghandi M,
    7. Dumont N, et al.
    WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019; 568: 551–6.
    OpenUrlCrossRef
  24. 24.↵
    2. Shi J,
    3. Wang E,
    4. Milazzo JP,
    5. Wang Z,
    6. Kinney JB,
    7. Vakoc CR.
    Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015; 33: 661–7.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Shalem O,
    3. Sanjana NE,
    4. Zhang F.
    High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet. 2015; 16: 299–311.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Bhullar KS,
    3. Lagaron NO,
    4. McGowan EM,
    5. Parmar I,
    6. Jha A,
    7. Hubbard BP, et al.
    Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018; 17: 48.
    OpenUrlCrossRefPubMed
  27. 27.↵
    2. Maurer G,
    3. Tarkowski B,
    4. Baccarini M.
    Raf kinases in cancer-roles and therapeutic opportunities. Oncogene. 2011; 30: 3477–88.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    2. Li W,
    3. Xu H,
    4. Xiao T,
    5. Cong L,
    6. Love MI,
    7. Zhang F, et al.
    MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014; 15: 554.
    OpenUrlCrossRefPubMed
  29. 29.↵
    2. Tang QL,
    3. Xie XB,
    4. Wang J,
    5. Chen Q,
    6. Han AJ,
    7. Zou CY, et al.
    Glycogen synthase kinase-3beta, NF-kappaB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 2012; 104: 749–63.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    2. Chou YS,
    3. Yen CC,
    4. Chen WM,
    5. Lin YC,
    6. Wen YS,
    7. Ke WT, et al.
    Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel. Int J Oncol. 2016; 48: 1187–94.
    OpenUrl
  31. 31.↵
    2. Rhee SH,
    3. Han I,
    4. Lee MR,
    5. Cho HS,
    6. Oh JH,
    7. Kim HS.
    Role of integrin-linked kinase in osteosarcoma progression. J Orthop Res. 2013; 31: 1668–75.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Wang X,
    3. Qin G,
    4. Liang X,
    5. Wang W,
    6. Wang Z,
    7. Liao D, et al.
    Targeting the CK1alpha/CBX4 axis for metastasis in osteosarcoma. Nat Commun. 2020; 11: 1141.
    OpenUrl
  33. 33.↵
    2. Scott MC,
    3. Temiz NA,
    4. Sarver AE,
    5. LaRue RS,
    6. Rathe SK,
    7. Varshney J, et al.
    Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma. Cancer Res. 2018; 78: 326–37.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    2. Chen S,
    3. Sanjana NE,
    4. Zheng K,
    5. Shalem O,
    6. Lee K,
    7. Shi X, et al.
    Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015; 160: 1246–60.
    OpenUrlCrossRefPubMed
  35. 35.
    2. Hart T,
    3. Chandrashekhar M,
    4. Aregger M,
    5. Steinhart Z,
    6. Brown KR,
    7. MacLeod G, et al.
    High-Resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015; 163: 1515–26.
    OpenUrlCrossRefPubMed
  36. 36.
    2. Parnas O,
    3. Jovanovic M,
    4. Eisenhaure TM,
    5. Herbst RH,
    6. Dixit A,
    7. Ye CJ, et al.
    A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. Cell. 2015; 162: 675–86.
    OpenUrlCrossRefPubMed
  37. 37.
    2. Wang T,
    3. Birsoy K,
    4. Hughes NW,
    5. Krupczak KM,
    6. Post Y,
    7. Wei JJ, et al.
    Identification and characterization of essential genes in the human genome. Science. 2015; 350: 1096–101.
    OpenUrlAbstract/FREE Full Text
  38. 38.
    2. Kong X,
    3. Kuilman T,
    4. Shahrabi A,
    5. Boshuizen J,
    6. Kemper K,
    7. Song JY, et al.
    Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature. 2017; 550: 270–4.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Zhou Y,
    3. Zhu S,
    4. Cai C,
    5. Yuan P,
    6. Li C,
    7. Huang Y, et al.
    High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature. 2014; 509: 487–91.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    2. Jia Y,
    3. Yun CH,
    4. Park E,
    5. Ercan D,
    6. Manuia M,
    7. Juarez J, et al.
    Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016; 534: 129–32.
    OpenUrlCrossRefPubMed
  41. 41.↵
    2. Ren R.
    Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005; 5: 172–83.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    2. Hu K,
    3. Dai HB,
    4. Qiu ZL.
    mTOR signaling in osteosarcoma: oncogenesis and therapeutic aspects (Review). Oncol Rep. 2016; 36: 1219–25.
    OpenUrlCrossRefPubMed
  43. 43.↵
    2. Li H,
    3. He Y,
    4. Hao P,
    5. Liu P.
    Identification of characteristic gene modules of osteosarcoma using bioinformatics analysis indicates the possible molecular pathogenesis. Mol Med Rep. 2017; 15: 2113–9.
    OpenUrl
  44. 44.↵
    2. Melero R,
    3. Uchiyama A,
    4. Castano R,
    5. Kataoka N,
    6. Kurosawa H,
    7. Ohno S, et al.
    Structures of SMG1-UPFs complexes: SMG1 contributes to regulate UPF2-dependent activation of UPF1 in NMD. Structure. 2014; 22: 1105–19.
    OpenUrlCrossRef
  45. 45.↵
    2. Hnilicova J,
    3. Hozeifi S,
    4. Stejskalova E,
    5. Duskova E,
    6. Poser I,
    7. Humpolickova J, et al.
    The C-terminal domain of Brd2 is important for chromatin interaction and regulation of transcription and alternative splicing. Mol Biol Cell. 2013; 24: 3557–68.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    2. McMahon SB,
    3. Van Buskirk HA,
    4. Dugan KA,
    5. Copeland TD,
    6. Cole MD.
    The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell. 1998; 94: 363–74.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    2. Li H,
    3. Cuenin C,
    4. Murr R,
    5. Wang ZQ,
    6. Herceg Z.
    HAT cofactor Trrap regulates the mitotic checkpoint by modulation of Mad1 and Mad2 expression. EMBO J. 2004; 23: 4824–34.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    2. Murr R,
    3. Loizou JI,
    4. Yang YG,
    5. Cuenin C,
    6. Li H,
    7. Wang ZQ, et al.
    Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat Cell Biol. 2006; 8: 91–9.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    2. Wang J,
    3. Shan M,
    4. Liu T,
    5. Shi Q,
    6. Zhong Z,
    7. Wei W, et al.
    Analysis of TRRAP as a Potential Molecular Marker and Therapeutic Target for Breast Cancer. J Breast Cancer. 2016; 19: 61–7.
    OpenUrl
  50. 50.↵
    2. Charles NA,
    3. Holland EC.
    TRRAP and the maintenance of stemness in gliomas. Cell Stem Cell. 2010; 6: 6–7.
    OpenUrlCrossRefPubMed
  51. 51.↵
    2. Jeong D,
    3. Kim H,
    4. Kim D,
    5. Ban S,
    6. Oh S,
    7. Ji S, et al.
    Protein kinase, membraneassociated tyrosine/threonine 1 is associated with the progression of colorectal cancer. Oncol Rep. 2018; 39: 2829–36.
    OpenUrl
  52. 52.↵
    2. Najjar A,
    3. Platzer C,
    4. Luft A,
    5. Assmann CA,
    6. Elghazawy NH,
    7. Erdmann F, et al.
    Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1. Eur J Med Chem. 2019; 161: 479–92.
    OpenUrl
  53. 53.↵
    2. Abe Y,
    3. Matsumoto S,
    4. Wei S,
    5. Nezu K,
    6. Miyoshi A,
    7. Kito K, et al.
    Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. J Biol Chem. 2001; 276: 44003–11.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    2. Capra M,
    3. Nuciforo PG,
    4. Confalonieri S,
    5. Quarto M,
    6. Bianchi M,
    7. Nebuloni M, et al.
    Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res. 2006; 66: 8147–54.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    2. Hideshima T,
    3. Cottini F,
    4. Nozawa Y,
    5. Seo HS,
    6. Ohguchi H,
    7. Samur MK, et al.
    p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017; 129: 1308–19.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords